Van Well Daan sold $47K of SOPH
Van Well Daan (Chief Legal Officer) sold 6,168 shares of SOPHiA GENETICS SA (SOPH) at $7.63 on 2026-09-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is routine and small, offering little actionable insight for traders.
Market read
Minor insider sell with negligible market impact.
What to watch
Potential tax or liquidity needs of the insider, not company fundamentals.
Background
SEC Form 4 filings disclose insider transactions; they are primary sources for such events.
Ticker impact
Chief Legal Officer Van Well Daan sold 6,168 shares for $47,089 via a 10b5-1 plan, reducing his stake to 338,884 shares.
Minimal downward pressure, likely negligible impact on share price.
The transaction size is small relative to market cap and was pre‑arranged, suggesting no new information about the company.
Market effects
None; the sale does not signal broader sector trends.
Limited to Swiss biotech market, no broader regional effect.
Insignificant on a global scale.
Counterpoint
The sale could be interpreted as a lack of confidence, but the pre‑arranged nature diminishes this reading.
Key entities
- CompanySOPHiA GENETICS SA
Swiss biotech firm listed on Nasdaq under SOPH.
- InsiderVan Well Daan
Chief Legal Officer of SOPHiA GENETICS.
